Loading…
TEVA-TICAGRELOR is a brand name for Ticagrelor, supplied as a tablet. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: 11/2024 1 INDICATION, 1.2 Geriatrics 11/2024 4 DOSAGE AND ADMINISTRATION, 4.1 Dosing Considerations 11/2024 4 DOSAGE AND ADMINISTRATION, 4.2 Recommended Dose and Dosage Adjustment 11/2024 7 WARNINGS AND PRECAUTIONS, General 11/2024 7 WARNINGS AND PRECAUTIONS, Cardiovascular 11/2024 7 WARNINGS AND PRECAUTIONS,…
Verbatim from this product's HC label. Tap a section to expand.
4 Geriatrics 11/2024 Table of Contents RECENT MAJOR LABEL CHANGES ............................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION .......................................................................
4 1 INDICATIONS ................................................................................................................. 1 Pediatrics ....................................................................................................................
2 Geriatrics ..................................................................................................................... 4 2 CONTRAINDICATIONS ...................................................................................................
4 4 DOSAGE AND ADMINISTRATION ................................................................................... 1 Dosing Considerations.................................................................................................
2 Recommended Dose and Dosage Adjustment ............................................................ 4 Administration ............................................................................................................ 5 Missed Dose ................................................................................................................
8 5 OVERDOSAGE ............................................................................................................... 8
and 14 CLINICAL TRIALS). 2 CONTRAINDICATIONS Teva-Ticagrelor (ticagrelor) is contraindicated in: 5 • Patients who are hypersensitive to this medication or to any ingredient in the formulation. For a complete listing of ingredients, see 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING.
• Patients who have active pathological bleeding such as peptic ulcer or intracranial hemorrhage (see 7 WARNINGS AND PRECAUTIONS and 8 ADVERSE REACTIONS). • Patients with a history of intracranial hemorrhage (see 7 WARNINGS AND PRECAUTIONS and 8 ADVERSE REACTIONS).
• Patients with moderate to severe hepatic impairment (see 4 DOSAGE AND ADMINISTRATION and 10 CLINICAL PHARMACOLOGY). g. ketoconazole, clarithromycin, nefazodone, ritonavir, and atazanavir) (see 7 WARNINGS AND PRECAUTIONS and
4 Geriatrics 11/2024 Table of Contents RECENT MAJOR LABEL CHANGES ............................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION .......................................................................
4 1 INDICATIONS ................................................................................................................. 1 Pediatrics ....................................................................................................................
2 Geriatrics ..................................................................................................................... 4 2 CONTRAINDICATIONS ...................................................................................................
4 4 DOSAGE AND ADMINISTRATION ................................................................................... 1 Dosing Considerations.................................................................................................
2 Recommended Dose and Dosage Adjustment ............................................................ 4 Administration ............................................................................................................ 5 Missed Dose ................................................................................................................
8 5 OVERDOSAGE ............................................................................................................... 8 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING ................................... 9 7 WARNINGS AND PRECAUTIONS ....................................................................................
1 Special Populations ................................................................................................... 1 Pregnant Women ..................................................................................................
Teva-Ticagrelor (ticagrelor) is contraindicated in: 5 • Patients who are hypersensitive to this medication or to any ingredient in the formulation. For a complete listing of ingredients, see 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING.
• Patients who have active pathological bleeding such as peptic ulcer or intracranial hemorrhage (see 7 WARNINGS AND PRECAUTIONS and 8 ADVERSE REACTIONS). • Patients with a history of intracranial hemorrhage (see 7 WARNINGS AND PRECAUTIONS and 8 ADVERSE REACTIONS).
• Patients with moderate to severe hepatic impairment (see
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Ticagrelor in Canada.
Know a brand we are missing in Canada? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
2 Breast-feeding ....................................................................................................... 3 Pediatrics ...............................................................................................................
4 Geriatrics .................................................................................................................... 15 8 ADVERSE REACTIONS ..................................................................................................
1 Adverse Reaction Overview ...................................................................................... 2 Clinical Trial Adverse Reactions ................................................................................. 3 Less Common Clinical Trial Adverse Reactions ..........................................................
4 Abnormal Laboratory Findings: Hematologic, Clinical Chemistry and Other Quantitative Data ................................................................................................................ 5 Post-Market Adverse Reactions ................................................................................
28 9 DRUG INTERACTIONS .................................................................................................. 1 Serious Drug Interactions ..........................................................................................
2 Drug Interactions Overview ...................................................................................... 3 Drug-Behavioural Interactions .................................................................................. 4 Drug-Drug Interactions .............................................................................................
5 Drug-Food Interactions ............................................................................................. 6 Drug-Herb Interactions .............................................................................................
7 Drug-Laboratory Test Interactions ............................................................................ 33 10 CLINICAL PHARMACOLOGY ......................................................................................... 1 Mechanism of Action.............................................................................................
2 Pharmacodynamics ............................................................................................... 3 Pharmacokinetics ..................................................................................................
36 11 STORAGE, STABILITY AND DISPOSAL ........................................................................... 40 12 SPECIAL HANDLING INSTRUCTIONS ............................................................................. 40 PART II: SCIENTIFIC INFORMATION .......................................................................................
41 13 PHARMACEUTICAL INFORMATION .............................................................................. 41 14 CLINICAL TRIALS ..........................................................................................................
1 Clinical Trials by Indication .................................................................................... 42 Acute Coronary Syndrome […]